Topics

PubMed Journals Articles About "Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy" RSS

04:54 EDT 6th April 2020 | BioPortfolio

Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy articles that have been published worldwide.

More Information about "Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy" on BioPortfolio

We have published hundreds of Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy news stories on BioPortfolio along with dozens of Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy Clinical Trials and PubMed Articles about Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy Companies in our database. You can also find out about relevant Foundation Medicine Touts Concordance Ahead Ruling Liquid Biopsy Drugs and Medications on this site too.

Showing "Foundation Medicine touts concordance ahead ruling liquid biopsy" PubMed Articles 1–25 of 21,000+

Liquid Biopsy in Breast Cancer: A Focused Review.

The role of liquid biopsy in cancer management has been gaining increased prominence in the past decade, with well-defined clinical applications now being established in lung cancer. Recently, the US Food and Drug Administration also approved the Therascreen RGQ polymerase chain reaction assay as a companion diagnostic assay to detect mutations in breast cancer for both tissue and liquid biopsies, bringing the role of liquid biopsy in breast cancer management to the fore. Its utility in other aspects of b...


Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions.

The potential of circulating cell-free DNA (cfDNA) analysis as a liquid biopsy has led to the development of several specialized measuring tools. Interest in the (pre-)analytical conditions of the liquid biopsy workflow has increased over the past few years.

Liquid Biopsy: A Tool for the Diagnostic and Prognostic Evaluation of Cancers.

Liquid biopsy is defined as the process of obtaining material for pathologic examination and analysis from body fluids. Liquid biopsy has been intensively researched for its clinical application in patients with solid malignancies, including melanoma and colon, breast, and lung cancers. This will become a standard and routine tool for the diagnostic and prognostic evaluation of all cancer types. This article provides an overview of liquid biopsy, its uses in cancer management, and its implications for nursi...


Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden.

We examined the impact of spatial, temporal, histologic and quantitative factors on concordance between TP53 alterations in tissue DNA versus in circulating tumor DNA (ctDNA). Four hundred and thirty-three patients underwent next-generation sequencing (NGS) in which both tissue and blood samples were evaluated. TP53 was detected in 258 of 433 patients (59.6%); 215 had tissue TP53 alterations (49.7%); 159, ctDNA (36.7%); and 116, both tissue and ctDNA (27.8%). Overall concordance rate between ctDNA and tissu...

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.

Analysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and documented form of "liquid biopsy" and provides real-time information on the molecular profile of the tumor without an invasive tissue biopsy.

Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.

The identification and quantification of actionable mutations are of critical importance for effective genotype-directed therapies, prognosis and drug response monitoring in patients with non-small-cell lung cancer (NSCLC). Although tumor tissue biopsy remains the gold standard for diagnosis of NSCLC, the analysis of circulating tumor DNA (ctDNA) in plasma, known as liquid biopsy, has recently emerged as an alternative and noninvasive approach for exploring tumor genetic constitution. In this study, we deve...

Endometrial liquid biopsy provides a miRNA roadmap of the secretory phase of the human endometrium.

Endometrial liquid biopsy (ELB) is a minimally invasive alternative for research and diagnosis in endometrial biology.

THE PRE-ANALYTICAL PHASE OF THE LIQUID BIOPSY.

The term 'liquid biopsy', introduced in 2013 in reference to the analysis of circulating tumour cells (CTCs) in cancer patients, was extended to cell-free nucleic acids (cfNAs) circulating in blood and other body fluids. CTCs and cfNAs are now considered diagnostic and prognostic markers, used as surrogate materials for the molecular characterisation of solid tumours, in particular for research on tumour-specific or actionable somatic mutations. Molecular characterisation of cfNAs and CTCs (especially at th...

Tumor-educated platelet as liquid biopsy in lung cancer patients.

Lung cancer is the most frequent cancer for males and third most frequent cancer for females. Targeted therapy drugs based on molecular alterations, such as angiogenesis inhibitors, epidermal growth factor receptor (EGFR) inhibitors, and anaplastic lymphoma kinase (ALK) inhibitors are important part of treatment of NSCLC. However, the quality of the available tumor biopsy and/or cytology material is sometimes not adequate to perform the necessary molecular testing, which has prompted the search for alternat...

Liquid Biopsy Quality Control and the Importance of Plasma Quality, Sample Preparation, and Library Input for Next Generation Sequencing Analysis.

Liquid biopsy is emerging as a non-invasive companion to traditional solid tumor biopsies. As next-generation sequencing (NGS) of circulating cell-free nucleic acids (cfNA = cfDNA and cfRNA) becomes common, it is important to understand the impact of sample preparation on quality, specificity, and sensitivity of liquid biopsy tests. Plasma samples are often limited and may have undesirable characteristics such as lipemia or hemolysis that contribute unwanted genomic DNA (gDNA) to the sample. Low cfDNA conce...

Liquid biopsy for rectal cancer: A systematic review.

The management of locally advanced rectal cancer (RC) is an evolving clinical field where the multidisciplinary approach can reach its best, and liquid biopsy for obtaining tumor-derived component such as circulating tumor DNA (ctDNA) might provide complementary informations.

Label-free liquid biopsy based on blood circulating DNA detection using SERS-based nanotechnology for nasopharyngeal cancer screening.

Development of a sensitive, rapid and easy-to-use liquid biopsy method is of imperative clinical value for point-of-care caner diagnostics. Here, a label-free and modification-free nanotechnology based on surface-enhanced Raman spectroscopy (SERS) was employed for DNA analysis. Using the SERS signals of phosphate backbone as internal standard, quantitative detection for nucleobases was achieved even at single base level. The method combined with principal component analysis and linear discriminant analysis ...

Concordances and predictors of biopsies in renal tumors.

Evaluate the concordance between the renal lesions biopsy's histology and the final histology of the surgical specimen according to histological subtype, and search for predictive factors of non-concordance.

Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.

Prostatic adenocarcinomas with cribriform morphology and/or intraductal carcinoma (CC/IDC) have higher recurrence and mortality rates after radiation and surgery. While the prognostic impact of these features is well-studied, concordance between CC/IDC on biopsy and prostatectomy has only recently gained attention. Our primary objective was to evaluate the diagnostic performance of biopsy for detecting CC/IDC in paired biopsy and prostatectomy specimens in a large contemporary cohort.

Liquid biopsy for diffuse intrinsic pontine glioma: an update.

Diffuse intrinsic pontine glioma (DIPG), otherwise known as diffuse midline glioma with H3K27M mutation, is a devastating brainstem glioma without a cure. Efforts are currently underway to better optimize molecular diagnoses through biological sampling, which today remains largely limited to surgical biopsy sampling. Surgical intervention is not without its risks, and therefore a preference remains for a less invasive modality that can provide biological information about the tumor. There is emerging eviden...

Protein Chemistry Looking Ahead: 8 Chemical Protein Synthesis Meeting 16-19 June 2019, Berlin, Germany.

The 8 Chemical Protein Synthesis meeting took place in Berlin in June 2019, covering broad topics in protein chemistry, ranging from synthetic methodology to applications in medicine and biomaterials. The meeting was also the culmination of the Priority Program SPP1623 on "Chemoselective Reactions for the Synthesis and Application of Functional Proteins" funded by the German Science Foundation (DFG) from 2012 to 2018. We present highlights from presentations at the forefront of the field, grouped into broad...

Correlation between transbronchial lung biopsy and lung cytology.

Respiratory diseases are an important cause of morbidity and mortality worldwide. Although conventional histopathology is the gold standard for their diagnosis, cytology is a useful adjunctive diagnostic test. In the present study we evaluated the efficacy of cytology in providing a rapid diagnosis. We included lesions which were both visible and not visible on bronchoscopy. We evaluated the role of bronchoalveolar lavage (BAL), brush cytology and imprint smears both separately and in combination, and compa...

Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study.

Hepatic artery infusion (HAI) and drug selection by liquid biopsy precision oncotherapy are under investigation for the multidisciplinary treatment of unresectable colorectal liver metastases (CRCLM) in progression after systemic therapy. Here, we compare the safety and efficacy of third-line HAI followed by target therapy with drug regimes selected by liquid biopsy precision oncotherapy to third-line systemic therapy with drug regimes selected partly by tissue biopsy precision oncotherapy, in a retrospecti...

Why We Might Not Need to Stress About Ruling Out Inducible Myocardial Ischemia.

The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.

There are few effective biomarkers for neuroendocrine tumors. Precision oncology strategies have provided liquid biopsies for real-time and tailored decision-making. This has led to the development of the first neuroendocrine tumor liquid biopsy (the NETest). The NETest represents a transcriptomic signature of neuroendocrine tumor (NETs) that captures tumor biology and disease activity. The data have direct clinical application in terms of identifying residual disease, disease progress and the efficacy of t...

Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).

Liquid biopsies (LB) are emerging in the oncology field, with promising data as new diagnostic, prognostic and treatment-monitoring tools. Squamous cell carcinoma of the head and neck (SCCHN) is a heterogenous disease and many challenges remain to improve patient outcomes. Liquid biopsy could be of interest at different stages of SCCHN disease, including better screening to diagnose more patients at an early stage, early detection of relapse after curative treatment, and the implementation of precision medi...

Cancer Liquid Biopsy Using Integrated Microfluidic Exosome Analysis Platforms.

Liquid biopsy serves as both a powerful non-invasive diagnostic tool for early cancer screening and a prognostic tool for monitoring cancer progression and treatment efficacy. Exosomes are promising biomarkers for liquid biopsy, since these nano-sized extracellular vesicles enrich proteins, lipids, mRNAs, and miRNAs from cells of origin, including cancer cells. Although exosomes are abundantly present in various body fluids, conventional exosome isolation and detection methods that rely on benchtop equipmen...

Negative Blood Cultures: Is There Value in Ruling Out Negatives Faster Than 5 Days?

Liquid biopsies for omics-based analysis in sentinel mussels.

Liquid biopsy of plasma is a simple and non-invasive technology that holds great promise in biomedical research. It is based on the analysis of nucleic acid-based biomarkers with predictive potential. In the present work, we have combined this concept with the FTA technology for sentinel mussels. We found that hemocytes collected from liquid biopsies can be readily fixed on FTA cards and used for long-term transcriptome analysis. We also showed that liquid biopsy is easily adaptable for metagenomic analysis...

Performance of Fetal Medicine Foundation Software for Pre-Eclampsia Prediction Upon Marker Customization: Cross-Sectional Study.

FMF2012 is an algorithm developed by the Fetal Medicine Foundation (FMF) to predict pre-eclampsia on the basis of maternal characteristics combined with biophysical and biochemical markers. Afro-Caribbean ethnicity is the second risk factor, in magnitude, found in populations tested by FMF, which was not confirmed in a Brazilian setting.


Quick Search